Supplementary Figure 6: BET bromodomain inhibition in MYCN-driven neuroblastoma. | Nature Genetics

Supplementary Figure 6: BET bromodomain inhibition in MYCN-driven neuroblastoma.

From: Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma

Supplementary Figure 6

a, Cropped western blot of vinculin and MYCN levels at 0, 1, 2, 4, 8, and 24 h of treatment with the BET inhibitor JQ1 (1 μM). The percentage of MYCN remaining versus 0 h is indicated. b, Box plots of the log2 mRNA fold change (versus 0 h) at active genes (defined by H3K27ac ChIP–seq signal at TSSs and expressed) with JQ1 (1 μM). Cell-normalized and traditional normalized log2 mRNA fold change levels are shown. Significance is denoted by Welch’s two-tailed t test: ***P < 1 × 10–9, **P < 1 × 10–6, *P < 1 × 10–3. c, Cell-normalized (left) and standard normalized (right) levels of the RPL22, HAND2, and ID2 transcripts during MYCN shutdown. Units are cell FPKM for triplicate biological replicates. Error bars represent s.d. d, Cell-normalized and standard normalized log2 fold change of gene expression changes ranked by total MYCN load during JQ1 treatment. Genes are grouped according to rank-ordered MYCN proximal load (promoters and enhancers). Error bars represent the 95% confidence interval (CI) of the mean. e, log2 fold change of gene expression changes of the top 5,000 genes ranked by total MYCN load during JQ1 treatment. Genes are grouped according to rank-ordered MYCN proximal load at promoters (left) or enhancers (right). Error bars represent the 95% confidence interval (CI) of the mean.

Back to article page